ArticleOncogene2005
Synergistic inhibition of human neuroblastoma-related angiogenesis by vinblastine and rapamycin.
Article in Oncogene, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 61 citations in OpenAlex.
- Article
- Therapeutic Innovation in Pediatric Neuroblastoma: Age and Stage-Specific Strategies from Prenatal to Early Childhood-A Review Article.Iranian journal of child neurology · 2025Review
- Technical Implications of the Chicken Embryo Chorioallantoic Membrane Assay to Elucidate Neuroblastoma Biology.International journal of molecular sciences · 2023Review
- CAM Model: Intriguing Natural Bioreactor for Sustainable Research and Reliable/Versatile Testing.Biology · 2023Review
- Metronomic Chemotherapy in Pediatric Oncology: From Preclinical Evidence to Clinical Studies.Journal of clinical medicine · 2022Review
- Characterization of Anti-Angiogenic Chemo-Sensitization via Longitudinal Ultrasound Localization Microscopy in Colorectal Carcinoma Tumor Xenografts.IEEE transactions on bio-medical engineering · 2022Article
- Applications of the Chick Chorioallantoic Membrane as an Alternative Model for Cancer Studies.Cells, tissues, organs · 2022Review
- The CAM Assay as an Alternative In Vivo Model for Drug Testing.Handbook of experimental pharmacology · 2021Article
- Patient Derived Chicken Egg Tumor Model (PDcE Model): Current Status and Critical Issues.Cells · 2019Review
- The chick chorioallantoic membrane (CAM) as a versatile patient-derived xenograft (PDX) platform for precision medicine and preclinical research.American journal of cancer research · 2018Review
- Evolving Significance and Future Relevance of Anti-Angiogenic Activity of mTOR Inhibitors in Cancer Therapy.Cancers · 2017Review
- The novel kinase inhibitor ponatinib is an effective anti-angiogenic agent against neuroblastoma.Investigational new drugs · 2016Article
- Structure based aggregation studies reveal the presence of helix-rich intermediate during α-Synuclein aggregation.Scientific reports · 2015Article
- AKT kinase pathway: a leading target in cancer research.TheScientificWorldJournal · 2013Review
- Curcumin modulates α-synuclein aggregation and toxicity.ACS chemical neuroscience · 2013Article
- Enhanced anti-tumor activity of a new curcumin-related compound against melanoma and neuroblastoma cells.Molecular cancer · 2010Article
- Targeting multiple angiogenic pathways for the treatment of neuroblastoma.Journal of pediatric surgery · 2010Article
- The Chick Embryo Chorioallantoic Membrane as an In Vivo Assay to Study Antiangiogenesis.Pharmaceuticals (Basel, Switzerland) · 2010Review
- Article
- Antiproliferative and pro-apoptotic activity of eugenol-related biphenyls on malignant melanoma cells.Molecular cancer · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to evaluate the synergistic antiangiogenic effect of low dose of vinblastine (VBL) and rapamycin (RAP) in neuroblastoma (NB). Both in vitro (endothelial cells proliferation assay; TUNEL assay; phosphatidylserine exposure and cell cycle analysis) and in vivo (chick embryo chorioallantoic membrane, CAM) assays were used. Each compound alone was able to induce a significant dose- and time-response inhibition of in vitro endothelial cells (EC) growth. Interaction index evaluation indicates that a synergistic effect was found when both drugs were combined at very low doses. Comparable effects were obtained when EC were preincubated with conditioned medium (CM) derived from the human NB cell line HTLA-230. Morphological changes were induced by each drug, and their combination resulted in a clear and stronger effect. Apoptosis was demonstrated by the TUNEL assay and confirmed by Annexin V-FITC staining of EC treated with VBL, showing an increase in the percentage of cells with a G2-M and sub-G1 DNA content, whereas in those treated with RAP a block in the G1 cell fraction and inhibition of progression to the S phase were observed. Here too, the combination resulted in a synergistic cell cycle arrest and induction of apoptosis. Similar results were obtained in vivo with the CAM assay. The angiogenic responses induced by HTLA-230-derived CM, NB tumor xenografts, and human NB biopsy specimens were inhibited by each drug and more significantly by their combination. The observation that these well-known drugs display synergistic effects as antiangiogenics when administered frequently at very low dose may be of significance in the designing of new ways of treating NB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.